Incidence of compromised microcirculation requiring invasive intervention (re‐exploration) (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes incidence of compromised microcirculation requiring invasive… compared with no LMWH (very low certainty).
1 finding from 1 review
Incidence of compromised microcirculation requiring invasive intervention (incision) (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes incidence of compromised microcirculation requiring invasive… compared with no LMWH (very low certainty).
1 finding from 1 review
Microvascular insufficiency due to vessel occlusion ‐ arterial occlusion (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes microvascular insufficiency due to vessel occlusion ‐ arterial… compared with no LMWH (very low certainty).
1 finding from 1 review
Microvascular insufficiency due to vessel occlusion ‐ venous occlusion (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes microvascular insufficiency due to vessel occlusion ‐ venous… compared with no LMWH (very low certainty).
1 finding from 1 review
Complication and adverse reactions ‐ wound bleeding (analysed by participant, · patients undergoing digital replantation after traumatic amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Success rate of replantation1 (analysed by participant) · patients undergoing digital replantation after traumatic amputation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Success rate of replantation1 (analysed by digit, · patients undergoing digital replantation after traumatic amputation
It is very uncertain whether low molecular weight heparin (LMWH) changes success rate of replantation1 (analysed by digit, compared with no LMWH (very low certainty).
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Pulmonary embolism · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in pulmonary embolism (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes minor bleeding (up to 3 months) compared with vitamin K antagonist (VKA) (very low certainty).
1 finding from 1 review
Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to lower symptomatic catheter‐related thrombosis (up to 3 months) compared with no LMWH (moderate certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no LMWH (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether low‐molecular‐weight heparin (LMWH) changes major bleeding (up to 3 months) compared with no LMWH (very low certainty).
1 finding from 1 review